Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix. - Wikidata - awgldk - TriplyDB

Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix.

Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix.

http://www.wikidata.org/entity/Q37371152

about

Advanced glycation: an important pathological event in diabetic and age related ocular disease Receptors for advanced glycosylation endproducts in human brain: role in brain homeostasis A receptor-based bioadsorbent to target advanced glycation end products in chronic kidney disease.Controlling the receptor for advanced glycation end-products to conquer diabetic vascular complications Quantitative analysis of glycation patterns in human serum albumin using 16O/18O-labeling and MALDI-TOF MS.Covalent binding antibodies suppress advanced glycation: on the innate tier of adaptive immunity.Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy The AGE-receptor in the pathogenesis of diabetic complications.Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation.Reduced acute vascular injury and atherosclerosis in hyperlipidemic mice transgenic for lysozyme.Regulation of RAGE for attenuating progression of diabetic vascular complications.Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis AGE restriction in diabetes mellitus: a paradigm shift.A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease Reactive immunization suppresses advanced glycation and mitigates diabetic nephropathy Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients.Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products.Non-enzymatic glycation and glycoxidation protein products in foods and diseases: an interconnected, complex scenario fully open to innovative proteomic studies.Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor.Human recombinant lysozyme downregulates advanced glycation endproduct-induced interleukin-6 production and release in an in-vitro model of human proximal tubular epithelial cells.Amelioration of oxidant stress by the defensin lysozyme.Neurodegenerative diseases of the retina and potential for protection and recovery Maillard Proteomics: Opening New Pages.

P2860

Q28365776-C30A4F47-AF3E-4314-A231-3090FA481B37 Q32085442-D8EF3AF3-7D6C-436B-856C-8A57A7FED37F Q33594667-1CD8EB9B-B977-4C51-87F9-A18B787F327A Q33609776-5F9D5F31-0A63-4B64-A3DC-20F98D3B2E9F Q33907748-1D5CCE74-B3C5-4495-9873-ECE2ED1BC58A Q34287672-B2C0FD40-9A1E-46B0-99BF-E83E8AE375DA Q34388076-66A13459-10AE-44F4-932A-AC0745F39562 Q34470639-630A7C2B-3852-44E1-A729-309DFCF07688 Q34747124-2FA8EB72-99FF-4F8F-9F40-0D3D5C3441F8 Q35221896-9C04DE06-AE44-4DFF-85EB-0994C439C924 Q35494903-4A087639-E2B6-4213-8244-12ACBFFE0ED1 Q35995060-715CAF73-5DCC-4E1C-837E-8A63FF189E9C Q36052417-44318919-BF53-4CCA-92B0-A6C49617A233 Q37003623-92EA933B-3A2F-4D12-B416-EC5A34656FF8 Q37097143-111A410B-608D-4E6D-AC4D-41DD26D5208C Q37181988-E4DDBCAA-0D7B-4E48-A0BE-E4428591AC7B Q38006722-96DE8C11-D70F-4FB4-B67A-0600F025A0C3 Q38096444-8BED4969-67BE-44FA-97D7-569915771C0F Q38151611-4CEF72E9-93F3-40F0-98AD-E718D1790AD3 Q38685706-C7D12C49-C64E-4C0B-B870-60B78749BF84 Q39027326-B7BA64F6-EE6B-4DDC-9C73-BF28981627AD Q40346041-80BDE30F-796E-4995-B391-A868A1803892 Q41997847-0DA4146C-D26C-4D7B-863D-37E338345786 Q47303198-E0E0E464-1A65-4E2A-A27E-14F077BF7F9A

P2860

Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix.

http://www.wikidata.org/entity/Q37371152

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 1997

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Depletion of reactive advanced ...... sing a lysozyme-linked matrix.

@en

Depletion of reactive advanced ...... sing a lysozyme-linked matrix.

@nl

type

label

Depletion of reactive advanced ...... sing a lysozyme-linked matrix.

@en

Depletion of reactive advanced ...... sing a lysozyme-linked matrix.

@nl

prefLabel

Depletion of reactive advanced ...... sing a lysozyme-linked matrix.

@en

Depletion of reactive advanced ...... sing a lysozyme-linked matrix.

@nl

P1433

Q37371152-4DDAD6C1-DD06-4A0D-88B1-7FE612EC5535

P1476

Q37371152-70C353E7-E2DE-4195-AF32-8AE36BD94178

P2093

Q37371152-16060A46-7B62-4B4A-B548-A546CC1E2CFB

Q37371152-1B2A6DDD-CA5B-40B1-8C96-B0C10251A8F3

Q37371152-229DEC20-2B3D-4EB7-9A74-3573C8B397DA

Q37371152-5D27B73D-ACE7-4AC8-8CF3-BB13F39FE673

P2860

Q37371152-00163739-C653-406B-BCA1-F8689C5269D8

Q37371152-0E4C9805-9BBE-42CA-846B-2CA270734010

Q37371152-14BA05FC-7974-42D1-B560-77B65521E37E

Q37371152-1A9315B3-8B6C-40A5-9E35-32A08CA7FBDF

Q37371152-25170920-5898-408D-8BB0-80AC1CF0E9CB

Q37371152-29684055-1DA6-4216-B376-2C287B44DC43

Q37371152-2D000B5F-FEA1-474A-80C7-1907B4F5632B

Q37371152-372B283D-4AAD-4DEF-8BB1-DDED69A64F2E

Q37371152-4DB7C9A1-C843-4D56-8CA2-C695B31016CE

Q37371152-500EE218-BC69-4878-AFF3-6BA66D64AD80

P304

Q37371152-A0FA7F6F-D0A6-4F40-AF88-63394E5F01FC

P31

Q37371152-1BB6A0E5-C95F-4B27-A140-C1FDE92C5497

P356

Q37371152-946821BB-8AB5-4A95-9ED1-7854548E93A0

P407

Q37371152-96C3B9EF-892B-440C-9BA6-DACE63FC2E2E

P433

Q37371152-1DB53552-9F97-43FA-9E7D-DFD1B2216F4F

P478

Q37371152-06DEA132-88F0-424C-96DA-4CC60C88A9E3

P577

Q37371152-76C3C308-A55B-40DB-9788-C51D04A29B34

P698

Q37371152-DA568A64-A98B-488A-B601-E88DB921E7E2

P932

Q37371152-E4EDDD0F-A46D-48BF-893E-ABF735682D81

P356

P1433

Journal of Clinical Investigation

P1476

Depletion of reactive advanced ...... sing a lysozyme-linked matrix.

@en

P2093

Fishbane S

http://www.w3.org/2001/XMLSchema#string

Li YM

http://www.w3.org/2001/XMLSchema#string

Mitsuhashi T

http://www.w3.org/2001/XMLSchema#string

Vlassara H

http://www.w3.org/2001/XMLSchema#string

P2860

Protein measurement with the Folin phenol reagent

Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications

beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis

Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy

Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes

Apolactoferrin structure demonstrates ligand-induced conformational change in transferrins.

The primary structure of glycoprotein III from bovine adrenal medullary chromaffin granules. Sequence similarity with human serum protein-40,40 and rat Sertoli cell glycoprotein.

Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death.

Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.

Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.

P304

847-854

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI119600

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P577

1997-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9259584

http://www.w3.org/2001/XMLSchema#string

P932

508257

http://www.w3.org/2001/XMLSchema#string